Generic Drugs – new study showing you trends, R&D progress, and predicted revenues
Where is the market for generic drugs heading? What are the commercial prospects for this market and related technologies? Visiongain’s new report shows you potential revenues and other trends to 2025, discussing data, opportunities and prospects.
Our new 250 page report provides 158 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, regional and national level. You will see financial results, interviews, trends, opportunities and revenue predictions.
Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces), company profiles and commercial developments. Read the full transcript of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
• Dr Atholl Johnston, Professor of Clinical Pharmacology at Barts and the London School of Medicine and Dentistry, Queen Mary University of London, and Director of the Laboratory of Analytical Services International Ltd
• Mr Peter Sharott, Pharmaceutical Adviser – Cancer & Blood, NHS England
What are the prospects for the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for regional markets to 2025. Future trends within each region are examined.
• US
• EU5
• Asia Pacific
• Emerging markets
• Rest of the world
Our analyses show sustained growth in the generic drugs market, particularly in the Asia-Pacific where less regulatory pressures will catalyse successful market entry.
You will discover individual revenue forecasts for 14 leading national markets to 2025. There are many commercial opportunities to exploit in both developed and developing countries.
• US
• China
• Japan
• Germany
• India
• France
• UK
• Russia
• Italy
• Brazil
• Mexico
• South Korea
• Turkey
• Spain
• Rest of the World
There will be growth in established pharma markets and in developing countries. Our analyses show that emerging market economies such as Brazil, Mexico, and South Korea will continue to achieve high revenue growth to 2025. Various economic and regulatory factors globally will influence the market.
Leading companies and potential for market growth
Competition within the market for generic drugs has increased dramatically over the last 30 years. The introduction of the Drug Price Competition and Patent Term Restoration Act has played a crucial role in this increase.
Overall global revenue for generic medicines will reach $214.4bn in 2015, our report reveals. We predict strong revenue growth from 2015 to 2025. Rising demand for prescription drugs, expanding healthcare coverage, payers favouring generics and changes to prescribing will increase sales to 2025.
Our work shows you what products and organisations hold greatest potential. See profiles of 11 leading companies, including these:
• Actavis
• Mylan
• Novartis
• Teva
• Abbott
• Pfizer
• Hospira
• Aspen
• Fresenius Kabi
• Sanofi
• Sun Pharma (Ranbaxy)
A company profile gives you the following information:
– Revenue forecast for generic drugs from 2015 to 2025
– Discussion of a company's activities and outlook
– Recent financial results
– Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, including alliances partnerships and joint ventures
Discover capabilities, progress, and commercial prospects, helping you stay ahead. What effects will improved regulatory processes have?
What issues will affect the generic drugs market?
Our new report lets you assess industry trends and outlooks. Our study discusses issues affecting generic drugs. You will find discussions, including qualitative analyses:
• Improving clarity around regulatory processes
• Government support for generic drug manufacturers
• Pricing pressures created by government cost-cutting initiatives
• Safety and quality concerns in the manufacturing process
• Consolidation among pharmacies and healthcare payers
• The uncertainties around patent extensions and exclusivities
• Sceptical physicians and the negative consumer perception of generics
• The changing socio-economic conditions impacting generic drug demand
• Emerging markets expected to drive generics volume growth
You will see discussions of technological, commercial, and economic matters, with emphasis on organisations developing technologies.
How the Generic Drugs Market Forecast 2015-2025: Opportunities for Leading Companies report helps you
In summary our 250 page report gives you the following knowledge:
• Revenues to 2025 for the overall generic drugs market – discover the industry’s prospects, finding promising areas for investments and revenues
• Revenue forecast to 2025 for leading regional markets – US, EU5, Emerging Markets and Asia-Pacific
• Revenue forecast to 2025 for 14 leading national markets – US, China, Japan, India, Germany, France, UK, Russia, Brazil, Mexico, Italy, South Korea, Turkey, Spain and RoW
• Assess leading companies – hear about products, results and strategies, including recent activities and outlook for 11 leading companies, including Novartis (Sandoz), Teva, Aspen, and Sanofi
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• Opinions from our survey, seeing interviews with industry authorities
• IP policy and other regulations – see what affects market access and entry
• Patent expiry – find prominent drug brands facing generic competition
• Trends of prescribers and healthcare payers – assess developments
You will find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for generic drugs market. You will find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Global Generic Drugs: Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Key Questions Answered By This Analytical Report
1.5 Who Is This Report For?
1.6 Methodology
1.7 Associated Reports
1.8 About Visiongain
2. An Introduction To Generic Drugs
2.1 What Are Generic Drugs?
2.1.1 Generic Active Ingredients
2.2 A Brief Overview Of The Pharmaceutical Industry
2.3 A Brief History Of Generic Drugs
2.3.1 The Hatch-Waxman Act: The Rise Of Generics
2.4 Demonstrating Bioequivalence: A Major Factor In Approving Generics
2.5 Types Of Generics - Authorised, Branded And Unbranded
2.6 Classification Of Generic Drugs Markets
2.7 Generic Substitution – Bad News For Big Pharma?
2.7.1 The 'Evergreening' Of Pharmaceutical Products
2.8 Regulation of Generic Drugs
2.8.1 Regulation in the US
2.8.1.1 Obtaining FDA Approval: NDAs And ANDAs
2.8.1.2 The Hatch-Waxman Act Title I: Promotion of Generic Drugs
2.8.1.3 The Hatch-Waxman Act Title II: Incentives for the Branded Industry
2.8.1.4 How Has The Hatch-Waxman Act Impacted Upon The US Pharmaceutical Market?
2.8.1.5 How The Timing Of Market Entry Influence Product Success
2.8.2 Regulation in Europe
2.8.2.1 EU Marketing Approval Procedures
2.8.2.2 The 8+2+1 Rule: EU Data Exclusivity
2.8.2.3 Supplementary Protection Certificates
2.8.2.4 Variation In Drug Development Regulations Between European Countries
2.8.2.5 The Move Towards Harmonisation of Standards
2.8.2.6 Europe’s Unitary Patent System And Its Likely Impact On Generics
2.8.3 Regulation In Japan
2.8.4 Regulation in China
2.9 Compulsory Licensing
2.10 Market Definition And Scope Of This Report
2.10.1 Market Sizing And Revenue Reporting
3. Generic Drugs Market, 2015-2025
3.1 The Global Generic Drugs Market: Market Overview
3.1.1 Segmenting The Global Generic Drugs Market
3.2 The Global Generic Drugs Market In 2014
3.3 Regional Distribution Of The Generic Drugs Market in 2014
3.4 The Global Generic Drugs Market: Sales Forecast 2015-2025
3.5 Generic Drugs: Regional Market Forecast 2015-2025
3.5.1 Changes In Generic Drug Regional Market Shares, 2015-2025
3.6 Leading National Markets For Generic Drugs: Market Forecast 2015-2025
3.7 National Markets That Will Drive Generic Drugs Growth
3.8 Changes In Market Shares By National Market, 2015-2025
3.9 The Global Market For Generic Drugs: Drivers and Restraints 2015-2025
4. US Generic Drugs Market, 2015-2025
4.1 Generic Drugs In The US: Market Overview
4.1.1 The Effects Of Generics On Healthcare Spending In The US
4.1.2 The Hatch-Waxman Act And Its Ongoing Effects
4.1.3 Consolidation In The Drug Development And Supply Chain Driving US Generics
4.2 US Historical Generic Penetration Rates
4.3 Leading Companies Operating Within The US Generic Drugs Market
4.3.1 The Increasing Acceptance Of Generics Amongst Consumers
4.3.2 Affordable Care Act: Expanding Medicare Coverage
4.4 The US Generic Drugs Market: Drivers And Restraints 2015-2025
4.5 The US Generic Drugs Market: Market Forecast 2015-2025
4.6 The US Generic Drugs Market – Strategic Analysis
4.6.1 Will Biosimilars Dictate The Future Of The US Generics Market?
4.6.2 The Backlog Of ANDA Applications
4.6.3 The Generic Drug User Fee Amendments (GDUFA)
4.6.4 Shortages Of Generic Drugs Will Restrain the Market
4.6.5 Is ‘Pay For Delay’ Restricting Fair Competition In The US Generics Market?
4.7 US Generic Drugs Market: A Range Of Factor Contributing To Growth
5. Leading European Generic Drugs Market, 2015-2025
5.1 European Generic Drugs: Market Overview
5.1.1 Europe: A Blend Of Mature and Developing Generic Drugs Markets
5.1.2 Factors Hindering Generic Penetration
5.1.3 Predominant Pricing Systems And Generic Penetration In European Markets
5.1.3.1 Lower Patient Co-Payments Drive Demand For Generics
5.1.3.2 The Effects Of Tendering For Generic Medicines
5.1.4 Will Europe Move Towards Free-Pricing Systems?
5.1.5 Challenges In The European Regulatory Environment
5.1.6 Ending ‘Pay For Delay’ Tactics in Europe
5.1.7 FDA And EMA Joint Data Sharing and Inspections
5.2 EU5 Generic Drugs Market: Market Forecast 2015-2025
5.3 EU5 Markets: Changing Market Shares By Country, 2015-2025
5.4 Germany: New Reforms To Medicinal Pricing May Impact Market Entry
5.4.1 German Generic Drugs Market: Generic Penetration by Volume, 2000-2014
5.4.2 German Generic Drugs Market: Generic Penetration by Value, 2000-2014
5.5 French Generic Drugs Market: Healthcare Reforms Impacting On Market Growth
5.5.1 French Generic Drugs Market: Sales Forecast 2015-2025
5.5.2 French Generic Drugs Market: Generic Penetration by Volume, 2000-2014
5.5.3 French Generic Drugs Market: Generic Penetration by Value, 2000-2014
5.6 UK Generic Drugs Market: A Mature Market With Growth Potentials
5.6.1 UK Generic Drugs Market: Sales Forecast 2015-2025
5.6.2 Cost Pressures And Demand-Side Policies Drive UK Generic Penetration
5.6.3 UK Generic Drugs Market: Generic Penetration by Volume, 2000-2014
5.6.4 UK Generic Drugs Market: Generic Penetration by Value, 2000-2014
5.6.5 Pharmacists As Enforcers Of Generic Substitution
5.7 Italian Generic Drugs Market: Branded Generics Hindering Overall Growth
5.7.1 The Tightening Of Italy’s Patent Legislations
5.7.2 The Italian Healthcare System – A Tale Of Falling Budgets
5.7.3 Italian Generic Drugs Market: Sales Forecast 2015-2025
5.7.4 Italian Generic Drugs Market: Generic Penetration by Volume, 2000–2014
5.7.5 Italian Generic Drugs Market: Generic Penetration by Value, 2000-2014
5.8 Spanish Generic Drugs Market: Light At The End Of The Tunnel
5.8.1 Cost-Containment Measures Helping To Boost Generic Drug Use
5.8.2 Spanish Generic Drugs Market: Sales Forecast 2015-2025
5.8.3 Spanish Generic Drugs Market: Generic Penetration by Volume, 2000–2014
5.8.4 Spanish Generic Drugs Market: Generic Penetration by Value, 2000-2014
6. Asia-Pacific Generic Drugs Market, 2015-2025
6.1 Generic Drugs In The Asia-Pacific Market: Market Overview
6.2 Japanese Generic Drugs Market: High Barriers To Entry
6.2.1 Public Perception Of Generics In Japan
6.2.2 Japanese Generic Drugs Market: Leading Companies
6.2.3 Japanese Generic Drugs Market: Sales Forecast 2015-2025
6.2.4 Japanese Generic Drugs Market: Generic Penetration by Volume, 2000–2014
6.2.5 Japanese Generic Drugs Market: Generic Penetration by Value, 2000-2014
6.2.6 Government Initiatives Driving Generic Penetration
6.2.7 Japanese Attitudes to Generic Drugs
6.3 Chinese Generic Drugs Market: Domestic Companies Dominate The Market Landscape
6.3.1 The Major Drivers Of Growth In The Chinese Generics Market
6.3.2 Chinese Generic Drugs Market: Sales Forecast 2015-2025
6.3.3 Compulsory Licensing Of Generic Drugs
6.3.4 Expansion Of Healthcare Coverage And Reimbursement
6.3.5 Chinese Generic Drugs Market: Generic Penetration by Volume, 2000–2014
6.3.6 Chinese Generic Drugs Market: Generic Penetration by Value, 2000-2014
6.3.7 The Impacts Of Price Controls And The Anhui Model
6.4 Indian Generic Drugs Market: Regulatory Failures Hindering Sales Growth
6.4.1 Leading Companies In The Indian Generic Drugs Market
6.4.2 Indian Generic Drugs Market: Sales Forecast 2015-2025
6.4.3 The Reforms To India’s Drug Prices Control Order And Its Likely Effects On Generic Drug Revenues
6.4.4 Expansion Of The National Healthcare Coverage Increases The Need For Generics
6.4.5 Has Recent Manufacturing Quality Failures Dented India’s Generics Growth?
7. Emerging Generic Drugs Market, 2015-2025
7.1 Generic Drugs In The Asia-Pacific Market: Market Overview
7.1.1 Emerging Economies: Improving Logistics And Better Infrastructure Catalysing Generics Growth
7.2 Brazil
7.2.1 Brazilian Generic Drugs Market: Sales Forecast 2015-2025
7.2.2 Generics To Facilitate Low-Income Earner’s Access To Medicines
7.2.3 Foreign Generic Drug Manufacturers Entering The Brazilian Market
7.3 South Korea – Treacherous Terrain For Generics
7.3.1 Pharmaceutical Price Controls And Measures Being Implemented In South Korea
7.3.1.1 KORUS FTA: The Free Trade Agreement Between South Korea And The US
7.3.1.2 The Free Trade Agreement Between Korea And The European Union
7.3.2 South Korean Generic Drugs Market: Sales Forecast 2015-2025
7.4 Russian Generic Drugs Market: Improving IP Protection To Aid Market Growth
7.4.1 Historical Trends In Russia’s Pharmaceutical Production And Distribution
7.4.2 The Pharma2020 Strategy - Healthcare and Industry Reform
7.4.3 Self-Medication In Russia And The Integral Role Of Pharmacies
7.4.4 Russian Generic Drugs Market: Sales Forecast 2015-2025
7.5 Turkey
7.5.1 Cost Cutting Measures And Their Effects On Turkish Generics
7.5.2 Will Turkey Become A Production Base For High Technology Products?
7.5.3 Turkish Generic Drugs Market: Sales Forecast 2015-2025
7.5.4 Regulatory Guidelines For Generic Drugs In Turkey
7.5.5 How Effective Has Turkey’s Health Transformation Programme Been?
7.6 Mexico
7.6.1 Government Programmes To Vitalise Generic Penetration In Mexico
7.6.2 Regulatory Changes And The Inception Of COFEPRIS
7.6.3 Mexican Generic Drugs Market: Sales Forecast 2015-2025
8. Leading Companies In The Generic Drugs Market, 2015-2025
8.1 Generic Drugs: Continuous Expansion To Rival
8.1.1 The Leading Companies In The Global Generics Market
8.2 Teva
8.2.1 Teva: Historical Financial And Performance Analysis, 2009-2013
8.2.2 Teva Generic Drugs Sales Forecast 2015-2025
8.2.3 Teva Generic Drugs Portfolio Analysis, 2015
8.2.3.1 High-Value Generics to Drive Teva’s Generics Growth?
8.2.3.2 The Shift Towards Innovation
8.2.3.3 Copaxone Leads Teva’s Moving Focus
8.2.3.4 The Threat Of Generic Erosion To Teva’s Products
8.2.4 What Does The Future Hold For Teva’s Generic Drugs Business?
8.3 Novartis
8.3.1 Novartis: Historical Financial And Performance Analysis, 2009-2013
8.3.2 Novartis Generic Drugs Sales Forecast 2015-2025
8.3.3 Novartis Generic Drugs Portfolio Analysis, 2015
8.3.3.1 Emphasis On Difficult-to-Manufacture Products
8.3.3.2 FDA Quality Concerns At Sandoz Manufacturing Plants
8.3.4 What Does The Future Hold For Novartis’ Generic Drugs Business?
8.4 Actavis (Allergan)
8.4.1 Actavis: Before The Mega-Merger
8.4.2 Actavis: Historical Financial And Performance Analysis, 2009-2013
8.4.3 Actavis: Generic Drugs Sales Forecast 2015-2025
8.4.4 Actavis: Recent Developments
8.4.4.1 Valeant and Mylan’s Failed Merger Attempts On Actavis
8.4.4.2 Actavis Acquisition Of Warner Chilcott
8.4.4.3 Actavis’ Work On Biosimilars
8.4.4.4 Exiting The Chinese Generics Market
8.4.4.5 Actavis’ Acquisition of Allergan
8.4.5 What Does The Future Hold For Actavis’ Generics Business?
8.5 Mylan
8.5.1 Mylan: Historical Financial And Performance Analysis, 2009-2013
8.5.2 Mylan Generic Drugs Sales Forecast 2015-2025
8.5.3 Mylan: Recent Developments
8.5.3.1 Acquisition Of Abbott’s Generic Business
8.5.3.2 Mylan To Double Manufacturing Capacity by 2016
8.5.3.3 Mylan Acquires Rights To GSK’s Advair, Diskus And Seretide
8.5.3.4 The Race To Market Copaxone Generics
8.5.3.5 Strategic Acquisition of Agila Expands Mylan’s Injectables Business
8.5.3.6 The Biosimilar Collaboration With India’s Biocon
8.5.4 What Does The Future Hold For Mylan’s Generic Drugs Business?
8.6 Pfizer
8.6.1 Pfizer: Historical Financial And Performance Analysis, 2009-2013
8.6.2 Pfizer’s Acquisition Of Hospira
8.6.3 Pfizer Generic Drugs Sales Forecast 2015-2025
8.6.4 Pfizer’s Restructuring Strategy
8.6.5 Future Prospects For Pfizer’s Generic Business
8.7 Abbott
8.7.1 Abbott: Historical Financial And Performance Analysis, 2009-2013
8.7.2 Abbott Generic Drugs Sales Forecast 2015-2025
8.7.3 Abbott: Recent Developments
8.7.3.1 Abbott After The Spin-Off Of AbbVie - The Established Products Business Segment
8.7.3.2 Acquisition of Solvay Pharmaceuticals and Piramal Healthcare Solutions
8.7.3.3 Acquisition Of CFR Pharmaceuticals Opens New Markets
8.7.4 What Does The Future Hold For Abbott’s Generic Drugs Business?
8.8 Aspen
8.8.1 Aspen: Historical Financial And Performance Analysis, 2010-2014
8.8.2 Aspen Generic Sales Forecast 2015-2025
8.8.3 Aspen: Recent Developments
8.8.3.1 Aspen Acquires Merck MSD’s Dutch API Plant
8.8.3.2 Acquisition Of GSK’s Anti-Thrombosis Brands
8.8.4 Future Outlook For Aspen’s Generic Business
8.9 Sanofi
8.9.1 Sanofi: Historical Financial And Performance Analysis, 2009-2013
8.9.2 Sanofi Generic Sales Forecast 2015-2025
8.9.3 Sanofi’s Strategies To Develop Generic Sales
8.9.3.1 Emerging Market Acquisitions
8.9.4 Future Prospects For Sanofi’s Generics Business
8.10 Hospira (Pfizer)
8.10.1 Hospira: Historical Financial And Performance Analysis, 2009-2013
8.10.2 Hospira: Recent Developments
8.10.2.1 Hospira’s Expansion Through Strategic Acquisitions
8.10.2.2 Manufacturing Concerns And Remediation Efforts
8.10.3 What Does The Future Hold For Hospira’s Generic Business?
8.11 Fresenius Kabi
8.11.1 Fresenius Kabi: Historical Financial And Performance Analysis, 2009-2013
8.11.2 Fresenius Kabi Generic Drugs Sales Forecast 2015-2025
8.11.3 InnoPharma Licensing Deal Bolsters Portfolio Grown Via Past Acquisitions
8.11.4 Fresenius Kabi’s Joint Venture With PT Soho Global Health
8.11.5 Future Prospects For Fresenius Kabi’s Generics Business
8.12 Sun Pharma/Ranbaxy
9. Qualitative Analysis Of The Generic Drugs Market, 2015-2025
9.1 Market Factors Influencing The Global Generic Drugs Market
9.2 SWOT Analysis Of The Global Generic Drugs Market, 2015-2025
9.2.1 Strengths
9.2.1.1 Improving Clarity Around Regulatory Processes
9.2.1.2 The Continuous Government Support For Generic Manufacturers – Precursors For Innovation
9.2.1.3 Higher Pace Of Growth Compared With Innovative Pharma
9.2.1.4 Globalisation And Its Impact On Manufacturing Capabilities
9.2.2 Weaknesses
9.2.2.1 Safety And Quality Concerns In The Manufacturing Process
9.2.2.2 The Non-Uniformity Of Excipients
9.2.2.3 The Uncertainty Around Patent Extensions And Exclusivities
9.2.2.4 Sceptical Physicians And The Negative Consumer Perception Of Generics
9.2.2.5 Inefficiencies In Certain Regulatory Approval Processes
9.2.3 Opportunities
9.2.3.1 Higher Value Biosimilars And Branded Generics
9.2.3.2 Patent Expiries Creating Opportunities
9.2.3.3 Changing Socio-Economic Conditions Impacting Generic Drug Demand
9.2.3.4 Emerging Markets – Expected To Drive Generics Volume Growth Over Time
9.2.4 Threats
9.2.4.1 Government Cost-Cutting Initiatives Impacting On Generic Drug Prices
9.2.4.2 The Complexity Surrounding Patents And Patent Expiries
9.2.4.3 Pharmacies And Healthcare Payer Consolidations
9.2.4.4 Possible Impacts Of A Declining Patent Pool
9.3 Porter’s Five Force Analysis Of The Global Generic Drugs Market, 2015-2025
9.3.1 Power Of Buyers
9.3.2 Power Of Suppliers
9.3.3 Rivalry Among Competitors
9.3.4 Threat of New Entrants
9.3.5 Threat of Substitutes
10. Expert Opinions from Our Primary Research
10.1 Interview With Dr Atholl Johnston, Professor Of Clinical Pharmacology At Barts And The London School Of Medicine And Dentistry, Queen Mary University of London, and Director Of The Laboratory Of Analytical Services International Ltd.
10.1.1 Cost – A Major Determinant Of Generic Drug Development And Usage
10.1.2 The Trade-offs Between Drug Cost And Drug Quality
10.1.3 The Regulatory Shortcoming Affecting Generic Drugs
10.1.4 On The Need To Standardise Toxicology And Associated Tests For Generics
10.1.5 Pharmacovigilance And The Need To Differentiate Generic Drug Products
10.1.6 Future Predictions For Bioequivalence In Generic Drugs
10.1.7 Therapeutic Areas That Will Drive The Growth Of Generic Drugs
10.2 Interview With Mr Peter Sharott, Pharmaceutical Adviser – Cancer & Blood, NHS England.
10.2.1 The Risk Of Non-Adherence And Treatment Failure
10.2.2 The Conflict Between Cost-Effectiveness And Patient Safety
10.2.3 Bioequivalence And Consistency In The Production And Packaging Of Generics
10.2.4 The Quest For Optimum Equilibrium In Generic Drugs Market Competition
10.2.5 Future Outlook For Generics
11. Conclusions
11.1 Overview Of Current Market Conditions And Market Forecast, 2014-2025
11.2 Generic Drugs As A Strategic Tool In Healthcare
11.3 Major Drivers Of Growth For Generic Drugs, 2015-2025
11.4 The Regulatory Landscape For Generic Drugs
11.5 Leading Generic Drug Manufacturers
11.6 Future Outlook For The Leading Regions Within The Global Generic Drugs Market, 2015-2025
11.7 Generic Penetration By Volume In Leading National Markets
11.8 What Does The Future Hold For The Global Generic Drugs Markets
List of Tables
Table 1.1 Global Generic Drugs Market: Market Forecast ($bn, AGR%, CAGR%) by National Markets, 2013-2025 (Altered Data)
Table 2.1 Types Of Drug Names, 2015
Table 3.1 The Global Generic Drugs Market: Market Size ($bn) and Market Share (%) by Leading National Markets, 2014
Table 3.2 The Global Generic Drugs Market: Market Size ($bn) and Market Share (%) by Region, 2014
Table 3.3 The Global Generic Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 3.4 The Global Generic Drugs Market: Market Forecast ($bn, AGR%, CAGR%) by Region, 2014-2025
Table 3.5 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2014, 2019, and 2025
Table 3.6 The Global Generic Drugs Market: Market Forecast ($bn, AGR%, CAGR%) by National Market, 2014-2025
Table 3.7 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2014-2019, 2019-2025, 2014-2025
Table 3.8 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2014, 2019, and 2025
Table 3.9 Global Generic Drugs Market: Market Drivers and Restraints, 2015-2025
Table 4.1 US Generic Drugs Market: Generic Penetration by Volume (%), 2004-2014
Table 4.2 US Generic Drugs Market: Market Drivers and Restraints, 2015-2025
Table 4.3 US Generic Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 5.1 The EU5 Generic Drugs Market: Revenue ($bn) and EU5 Share (%) by Country, 2014
Table 5.2 EU5 Generic Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 5.3 The EU5 Generic Drugs Market: Market Share (%) by Country, 2014, 2019, 2025
Table 5.4 The German Generic Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 5.5 German Generic Drugs Market: Generic Penetration by Volume (%), 2000-2014
Table 5.6 German Generic Drugs Market: Generic Penetration by Value (%), 2000-2014
Table 5.7 The French Generic Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 5.8 French Generic Drugs Market: Generic Penetration by Volume (%), 2000-2014
Table 5.9 French Generic Drugs Market: Generic Penetration by Value (%), 2000-2014
Table 5.10 The UK Generic Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 5.11 UK Generic Drugs Market: Generic Penetration by Volume (%), 2000-2014
Table 5.12 UK Generic Drugs Market: Generic Penetration by Value (%), 2000-2014
Table 5.13 The Italian Generic Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 5.14 Italian Generic Drugs Market: Generic Penetration by Volume (%), 2000-2014
Table 5.15 Italian Generic Drugs Market: Generic Penetration by Value (%), 2000-2014
Table 5.16 The Spanish Generic Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 5.17 Spanish Generic Drugs Market: Generic Penetration by Volume (%), 2000-2014
Table 5.18 Spanish Generic Drugs Market: Generic Penetration by Value (%), 2000-2014
Table 6.1 The Japanese Generic Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 6.2 Japanese Generic Drugs Market: Generic Penetration by Volume (%), 2000-2014
Table 6.3 Japanese Generic Drugs Market: Generic Penetration by Value (%), 2000-2014
Table 6.4 The Chinese Generic Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 6.5 Chinese Generic Drugs Market: Generic Penetration by Volume (%), 2000-2014
Table 6.6 Chinese Generic Drugs Market: Generic Penetration by Value (%), 2000-2014
Table 6.7 The Indian Generic Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 7.1 The Brazilian Generic Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 7.2 The South Korean Generic Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 7.3 The Russian Generic Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 7.4 The Turkish Generic Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 7.5 The Mexican Generic Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 8.1 Top Generic Drugs Manufacturers: Total Revenue ($bn) and Generic Drugs Revenue ($bn), 2013, 2014
Table 8.2 Teva: Company Overview, 2013-2014
Table 8.3 Teva: Historical Generic Drugs Sales ($bn, AGR %), 2009-2013
Table 8.4 Teva: Generic Drugs Revenue Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 8.5 Novartis: Overview, 2013-2014
Table 8.6 Novartis: Historical Generic Drugs Sales ($bn, AGR %), 2009-2013
Table 8.7 Novartis: Generic Drugs Revenue Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 8.8 Actavis: Company Overview, 2013-2014
Table 8.9 Actavis: Historical Generic Drugs Sales ($bn, AGR %), 2009-2013
Table 8.10 Actavis: Generic Drugs Revenue Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 8.11 Mylan: Company Overview, 2013-2014
Table 8.12 Mylan: Historical Generic Drugs Sales ($bn, AGR %), 2009-2013
Table 8.13 Mylan: Generic Drugs Revenue Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 8.14 Pfizer: Company Overview, 2013-2014
Table 8.15 Pfizer: Historical ‘Established Products’ Drugs Sales ($bn, AGR %), 2009-2013
Table 8.16 Pfizer: Generic Drugs Revenue Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 8.17 Abbott: Company Overview, 2013-2014
Table 8.18 Abbott: Historical Generic Drugs Sales ($bn, AGR %), 2009-2013
Table 8.19 Abbott: Generic Drugs Revenue Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 8.20 Aspen: Company Overview, 2013-2014
Table 8.21 Aspen: Historical Revenue ($bn, bn Rand, AGR %), 2010-2014
Table 8.22 Aspen: Generic Drugs Revenue Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 8.23 Sanofi: Company Overview, 2013-2014
Table 8.24 Sanofi: Historical Generic Drugs Sales ($bn, bn Euros, AGR %), 2009-2013
Table 8.25 Sanofi: Generic Drugs Revenue Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 8.26 Hospira: Company Overview, 2013-2014
Table 8.27 Hospira: Historical Specialty Injectables Sales ($bn, AGR %), 2009-2013
Table 8.28 Fresenius Kabi: Company Overview, 2013-2014
Table 8.29 Fresenius Kabi: Historical Generic Drugs Sales ($bn, bn Euros, AGR %), 2009-2013
Table 8.30 Fresenius Kabi: Generic Drugs Revenue Forecast ($bn, AGR%, CAGR%), 2014-2025
Table 9.1 SWOT Analysis of the Generic Drugs Market, 2015-2025
Table 9.2 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2014-2025
Table 11.1 Global Generic Drugs: Market Forecast ($bn, CAGR%), 2014, 2017, 2021, 2025
Table 11.2 Top Generic Drug Manufacturers: Generic Drugs Revenue ($bn), 2014
Table 11.3 Global Generic Drugs: Market Forecast ($bn) by National Markets, 2014, 2017, 2021, 2025
Table 11.4 Generic Drug Penetration by Volume in Leading National Markets (%), 2014
List of Figures
Figure 1.1 Japanese Generic Drugs Market: Market Forecast ($bn, AGR%), 2013-2025 (Altered Data)
Figure 2.1 EU Data Exclusivity For Generics: Possible Scenarios, 2015
Figure 3.1 The Global Generic Drugs Market: Market Size ($bn) by Leading National Markets, 2014
Figure 3.2 The Global Generic Drugs Market: Market Size ($bn) by Region, 2014
Figure 3.3 Global Generic Drugs Market: Market Forecast ($bn, AGR%), 2014-2025
Figure 3.4 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2014
Figure 3.5 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2019
Figure 3.6 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2025
Figure 3.7 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2014-2019
Figure 3.8 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2019-2025
Figure 3.9 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2014-2025
Figure 3.10 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2014
Figure 3.11 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2019
Figure 3.12 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2025
Figure 4.1 US Generic Drugs Market: Generic Penetration by Volume (%), 2004-2014
Figure 4.2 US Generic Drugs Market: Market Forecast ($bn, AGR%), 2014-2025
Figure 5.1 The EU5 Generic Drugs Market: Revenues ($bn) by Country, 2014
Figure 5.2 Germany, France, UK, Italy, and Spain Generic Drugs Market: Market Forecast ($bn), 2014-2025
Figure 5.3 The EU5 Generic Drugs Market: Market Share (%) by Country, 2014
Figure 5.4 The EU5 Generic Drugs Market: Market Share (%) by Country, 2019
Figure 5.5 The EU5 Generic Drugs Market: Market Share (%) by Country, 2025
Figure 5.6 The German Generic Drugs Market: Market Forecast ($bn, AGR%), 2014-2025
Figure 5.7 German Generic Drugs Market: Generic Penetration by Volume (%), 2000-2014
Figure 5.8 German Generic Drugs Market: Generic Penetration by Value (%), 2000-2014
Figure 5.9 The French Generic Drugs Market: Market Forecast ($bn, AGR%), 2014-2025
Figure 5.10 French Generic Drugs Market: Generic Penetration by Volume (%), 2000-2014
Figure 5.11 French Generic Drugs Market: Generic Penetration by Value (%), 2000-2014
Figure 5.12 The UK Generic Drugs Market: Market Forecast ($bn, AGR%), 2014-2025
Figure 5.13 UK Generic Drugs Market: Generic Penetration by Volume (%), 2000-2014
Figure 5.14 UK Generic Drugs Market: Generic Penetration by Value (%), 2000-2014
Figure 5.15 The Italian Generic Drugs Market: Market Forecast ($bn, AGR%), 2014-2025
Figure 5.16 Italian Generic Drugs Market: Generic Penetration by Volume (%), 2000-2014
Figure 5.17 Italian Generic Drugs Market: Generic Penetration by Value (%), 2000-2014
Figure 5.18 The Spanish Generic Drugs Market: Market Forecast ($bn, AGR%), 2014-2025
Figure 5.19 Spanish Generic Drugs Market: Generic Penetration by Volume (%), 2000-2014
Figure 5.20 Spanish Generic Drugs Market: Generic Penetration by Value (%), 2000-2014
Figure 6.1 Japan, China, and India Generic Drugs Market: Market Forecast ($bn), 2014-2025
Figure 6.2 The Japanese Generic Drugs Market: Market Forecast ($bn, AGR%), 2014-2025
Figure 6.3 Japanese Generic Drugs Market: Generic Penetration by Volume (%), 2000-2014
Figure 6.4 Japanese Generic Drugs Market: Generic Penetration by Value (%), 2000-2014
Figure 6.5 The Chinese Generic Drugs Market: Market Forecast ($bn, AGR%), 2014-2025
Figure 6.6 Japanese Generic Drugs Market: Generic Penetration by Volume (%), 2000-2014
Figure 6.7 Chinese Generic Drugs Market: Generic Penetration by Value (%), 2000-2014
Figure 6.8 The Indian Generic Drugs Market: Market Forecast ($bn, AGR%), 2014-2025
Figure 7.1 Brazil, South Korea, Russia, Turkey, and Mexico Generic Drugs Market: Market Forecast ($bn), 2014-2025
Figure 7.2 The Brazilian Generic Drugs Market: Market Forecast ($bn, AGR%), 2014-2025
Figure 7.3 The South Korean Generic Drugs Market: Market Forecast ($bn, AGR%), 2014-2025
Figure 7.4 The Russian Generic Drugs Market: Market Forecast ($bn, AGR%), 2014-2025
Figure 7.5 The Turkish Generic Drugs Market: Market Forecast ($bn, AGR%), 2014-2025
Figure 7.6 The Mexican Generic Drugs Market: Market Forecast ($bn, AGR%), 2014-2025
Figure 8.1 Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2014
Figure 8.2 Teva: Historical Generic Drugs Sales ($bn, AGR %), 2009-2013
Figure 8.3 Teva: Generic Drugs Revenue Forecast ($bn, AGR%), 2014-2025
Figure 8.4 Novartis: Historical Generic Drugs Sales ($bn, AGR %), 2009-2013
Figure 8.5 Novartis: Generic Drugs Revenue Forecast ($bn, AGR%), 2014-2025
Figure 8.6 Actavis: Historical Generic Drugs Sales ($bn, AGR %), 2009-2013
Figure 8.7 Actavis: Generic Drugs Revenue Forecast ($bn, AGR%), 2014-2025
Figure 8.8 Mylan: Historical Generic Drugs Sales ($bn, AGR %), 2009-2013
Figure 8.9 Mylan: Generic Drugs Revenue Forecast ($bn, AGR%), 2014-2025
Figure 8.10 Pfizer: Historical ‘Established Products’ Drugs Sales ($bn, AGR %), 2009-2013
Figure 8.11 Pfizer: Generic Drugs Revenue Forecast ($bn, AGR%), 2014-2025
Figure 8.12 Abbott: Historical Generic Drugs Sales ($bn, AGR %), 2009-2013
Figure 8.13 Abbott: Generic Drugs Revenue Forecast ($bn, AGR%), 2014-2025
Figure 8.14 Aspen: Historical Revenue ($bn, AGR %), 2009-2013
Figure 8.15 Aspen: Generic Drugs Revenue Forecast ($bn, AGR%), 2014-2025
Figure 8.16Sanofi: Historical Generic Drugs Sales (bn Euros, AGR %), 2009-2013
Figure 8.17 Sanofi: Generic Drugs Revenue Forecast ($bn, AGR%), 2014-2025
Figure 8.18 Hospira: Historical Specialty Injectables Sales ($bn, AGR %), 2009-2013
Figure 8.19 Fresenius Kabi: Historical Generic Drugs Sales (bn Euros, AGR %), 2009-2013
Figure 8.20 Fresenius Kabi: Generic Drugs Revenue Forecast ($bn, AGR%), 2014-2025
Figure 9.1 World 65+ Population Forecast: Size (m), AGR (%), 2014-2025
Figure 9.2 Porter’s Five Force Analysis of the Global Generic Drugs Market, 2015
Figure 11.1 Global Generic Drugs: Market Forecast ($bn), 2014, 2017, 2021, 2025
Figure 11.2 US, Japan and EU5 Generic Drugs Market: Market Forecast ($bn), 2014-2025
Figure 11.3 BRIC Generic Drugs Market: Market Forecast ($bn), 2014-2025
Figure 11.4 Mexico, South Korea, and Turkey Generic Drugs Market: Market Forecast ($bn), 2014-2025
Figure 11.5 Generic Drug Penetration by Volume in Leading National Markets (%), 2014
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
